Current perspectives on the role of neurosteroids in pms and depression

International Review of Neurobiology

Volumn 46, Issue , 2001, Pages 479-492

  Griffin, Lisa D ^a   Conrad, Susan C ^a   Mellon, Synthia H ^a,b  

^a Department of Neurology ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELTANOLONE;

ANIMAL; BRAIN LEVEL; DEPRESSION; FEMALE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PREMENSTRUAL SYNDROME; REVIEW;

ANIMALS; BRAIN CHEMISTRY; DEPRESSION; FEMALE; HUMANS; PREGNANOLONE; PREMENSTRUAL SYNDROME;

EID: 0035237044     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0074-7742(01)46073-9     Document Type: Article

References (49)

1. American Psychiatrie Association. (1994). "Diagnostic and statistical manual of mental disorders" (4th edition). Washington, DC.
2. Bicikova, M., Dibbelt, L., Hill, M., Hampl, R., and Stârka, L. (1998). Allopregnanolone in women with premenstrual syndrome. Harm. Metab. Res. 30, 227-230.
3. Compagnone, N. A., and Mellon, S. H. (2000). Neurosteroids: Biosynthesis and function of these novel neuroinodnlators. Front. Xrumendomnol. 21, 1-56.
4. Dhanvantari, S., and Wiebe, J. P. (1994). Suppression of follicle-stimulating hormone by the gonadal- and neurosteroid 3 alpha-hydroxy-4-pregnen-20-one involves actions at the level of the gonadotrope membrane/calcium channel. Endocrinology 134, 371-376.
5. Dimmock, P. W., Wyatt, K. M., Jones, P. W., and O'Brien, P. M. (2000). Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic review. Lancet 356, 1131-1136.
6. EndicottJ. (1993). The menstrual cycle and mood disorders./ Affect. Disord. 29, 193-200.
7. Endicott,J., Amsterdam,J., Eriksson, E., Frank, E., Freeman, E., Hirschfeld, R., Ling, F., Parry, B., Pearlstein, T., RosenbaumJ., Rubinow, D., Schmidt, P., Severino, S., Steiner, M., Stewart, D. E., and Thys-Jacobs, S. (1999). Is premenstrual dysphoric disorder a distinct clinical entity?/ Womens Health Gend. Based Me.d. 8, 663-679.
8. Eriksson, E. (1999). Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int. Clin. Psychopharmacol. 14 Suppl 2, S27-S33.
9. Freeman, E. W., and Halbreich, U. (1998). Premenstrual syndromes. Psychopharmacol. Bull. 34, 291-295.
10. Griffin, L. D., and Mellon, S. H. (1999). Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sei. USA 96, 13512-13517.
11. Griffin, L. D., and Mellon, S. H. (2001). Biosynthesis of the neurosteroid 3a-hydroxy-4prenene-20-one (3a-HP), a specific inhibitor of FSH release. Endocronology (In Press).
12. Halbreich, U. (1999). Premenstrual syndromes: closing the 20th century chapters. Curr. Opin. Obstet. Gynecol. 11, 265-270.
13. Hammarback, S., and Backström, T. (1988). Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet, fynecol. Scand. 67, 159-166.
14. Hammarback, S., Damber, J. E., and Backström, T. (1989). Relationship between symptom severity and hormone changes in women with premenstrual syndrome.J. Clin. Endocrinol. Metab.68, 125-130.
15. Hammarback, S., Ekholm, U. B., and Backström, T. (1991). Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol. (Copenhagen) 125, 132-137.
16. Kessel, B. (2000). Premenstrual syndrome. Advances in diagnosis and treatment. Obstet. Cynecol. Clin. North Am. 27, 625-639.
17. Khisti, R. T., and Chopde, C. T. (2000). Serotonergic agents modulate antidepressant-likel effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice. Brain Res. 865, 291-300.
18. Masand, P. S., and Gupta, S. (1999). Selective serotonin-reuptake inhibitors: An update. Hary. Rev. Psychiatry 7, 69-84.
19. Menkes, D. B., Taghavi, E., Mason, P. A., and Howard, R. G. (1993). Fluoxetine's spectrum of action in premenstrual syndrome. Int. Clin. Psychopharmacol. 8, 95-102.
20. Menkes, D. B., Taghavi, E., Mason, P. A., Spears, G. F., and Howard, R. G. (1992). Fluoxetine treatment of severe premenstrual syndrome. Er. Med. J. 305, 346-347.
21. Monteleone, P., Luisi, S., Tonetti, A., Bernard!, F., Genazzani, A. D., Luisi, M., Petraglia, F., and Genazzani, A. R. (2000). Allopregnanolone concentrations and premenstrual syndrome. Eur.J. Endocrinol. 142, 269-273.
22. Morrow, A. L., Pace,J. R., Purdy, R. H., and Paul, S, M. (1990). Gharacterization of steroid interactions with gamma-aminobutyric acid receptor-gated chloride ion channels: Evidence for multiple steroid recognition sites. Mol. Pharmacol. 37, 263-270.
23. Pearlstein, T. B., Frank, E., Rivera-Tovar, A., Thoft, J. S., Jacobs, E., and Mieczkowski, T. A. (1990). Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder./ Affect. Disord. 20, 129-134.
24. Rapkin, A. J. (1992). The role of serotonin in premenstrual syndrome. Clin. Obstet, Gynecol. 35, 629-636.
25. Rapkin, A.J., Edelmuth, E., Chang, L. C., Reading, A. E., McGuire, M. T., and Su, T. P. (1987). Whole-blood serotonin in premenstrual syndrome. Obstet. Gynecol. 70, 533-537.
26. Rapkin, A. J., Morgan, M., Goldman, L., Brann, D. W., Simone, D., and Mahesh, V. B. (1997). Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet. Gynecol. 90, 709-714.
27. Rojansky, N., Halbreich, U., Zander, K., Barkai, A., and Goldstein, S. (1991). Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol. Obstet. Invest. 31, 146-152.
28. Romeo, E., Strohle, A., Spalletta, G., di Michèle, F., Hermann, B., Holsboer, F., Pasini, A., and Rupprecht, R. ( 1998). Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry 155, 910-913.
29. Rubinow, D. R., and Schmidt, P. J. (1995). The neuroendocrinology of menstrual cycle mood disorders. Ann. NY Ac ad. Sri. 771, 648-659.
30. Rubinow, D. R., Schmidt, P. J., and Roca, C. A. (1998). Hormone measures in reproductive endocrine-related mood disorders: diagnostic issues. Psychopharmacol. Bull. 34, 289-290.
31. Schmidt, P.J., Purdy, R. H., Moore, P. H., Paul, S. M., and Rubinow, D. R. (1994). Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects.J. Clin. Endocrinol. Metab. 79, 1256-1260.
32. Steiner, M. (1992). Female-specific mood disorders. Clin. Obstet. Gynecol. 35, 599-611.
33. Steiner, M. (1997). Premenstrual syndromes. An nu. Rn>. Med. 48, 447-455.
34. Steiner, M., and Pearlstein, T. (2000). Premenstrual dysphoria and the serotonin system: Pathophysiology and treatment. J. Clin. Psychiatry. 61, 17-21.
35. Steiner, M., Steinberg, S., Stewart, D.,Arter, D., Berger, C., Reid, R., Grover, D., and Streiner, D. (1995). Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. X. Engl. J. Med. 332, 1529-1534.
36. Stone, A. B., Pearlstein, T. B., and Brown, W. A. (1990). Fluoxetine in the treatment of premenstrual syndrome. Psychopharmacol. Bull. 26, 331-335.
37. Stone, A. B., Pearlstein, T. B., and Brown, W. A. (1991). Fluoxetine in the treatment of late luteal phase dysphoric disorder./ Clin. Psychiatry 52, 290-293.
38. Su, T. P., Schmidt, P. J., Danaceau, M. A., Tobin, M. B., Rosenstein, D. L., Murphy, D. L., and Rubinow, D. R. (1997). Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmncology 16, 346-356.
39. Sundström, I., Andersson, A., Nyberg, S., Ashbrook, D., Purdv, R. H., and Bäckström, T. (1988). Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Xeuroendocrinology 67, 126-138.
40. Uzunov, D. P., Cooper, T. B., Costa, E., and Guidotti, A. (1996). Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Natl. Acad. Sei. USA 93, 12599-12604.
41. Uzunova, V., Sheline, Y., Davis, J. M., Rasmusson, A., UJunov, D. P., Costa, E., and Guidotti, A. (1998). Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sei. USA 95, 3239-3244.
42. Wang, M., Seippel, L., Purdy, R. H., and backstrom, T. (1996). Relationship between symptom severity and steroid variation in women with premenstrual syndrome: Study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane- 3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one./ Clin. Endocrinol. Metab. 81, 1076-1082.
43. Wiebe, J. P., Boushy, D., and Wolfe, M. (1997). Synthesis, metabolism and levels of the neuroactive steroid, 3alpha-hydroxy-4-pregnen-2()-one (3alphaHP), in rat pituitaries. Brain Res. 764,158-166.
44. Wiebe, J. P., Dhanvantari, S., Watson, P. H., and Huang, Y. (1994). Suppression in gonadotropes of gonadotropin-releasing hormone-stimulated follicle-stimulating hormone release by the gonadal- and neurosteroid 3 alpha-hydroxy-4-pregnen-20-one involves cytosolic calcium. Endocrinology 134, 377-382.
45. Wiebe, J. P., and Wood, P. H. (1987). Selective suppression of follicle-stimulating hormone by 3 alpha-hydroxy-4-pregnen-20-one, a steroid found in Sertoli cells. Endocrinology 120, 2259-2264.
46. Wood, P. H., and Wiebe,P. (1989). Selective suppression of follicle-stimulating hormone secretion in anterior pituitary cells by the gonadal steroid 3 alpha-hydroxy-4-pregnen-20-one. Endocrinology 125, 41-48.
47. Wood, S. H., Mortola, J. F., Chan, Y. F., MoossaJadeh, F., and Yen, S. S. (1992). Treatment of premenstrual syndrome with fluoxetine: A double-blind, placebo-controlled, crossover study. Obstet. C.ynecoi 80, 339-344.
48. Wurtman,J.J. (1993). Depression and weight gain: The serotonin connection. J. Affect. Disord. 29,183-192.
49. Yatham, L. N. (1993). Is 5HT1A receptor subsensitivity a trait marker for late luteal phase dysphoric disorder? A pilot study. Can.Psychiatry 38, 662-664.